Page results
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
UCLH is managing one of the three cancer hubs across London, so that during the COVID-19 coronavirus pandemic cancer surgery is available for patients with the most immediate needs.
-
One of our patients who is recovering from COVID-19 has been appearing across national media as she recounts her story and thanks the staff who saved her life.
-
The special haematology service provides a comprehensive investigation of haemolytic amaemia, haemoglobinopathies and red cell enzymopathy.
-
Information on how we ask for your consent to treatment, and Martha's Rule.
-
Patients recovering from coronavirus have spoken movingly about the physical and emotional legacy of the disease.
-
Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.
-
Breathing aids developed by engineers at UCL, UCLH and Mercedes-AMG High Performance Powertrains have been delivered to 40 NHS hospitals across the country.
File results
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0401 - Hospital treatments for abortion complications
-
FOI/2024/0380 - Appraisal review/ Responsible Officer/ Revalidation Officer
-
FOI/2024/0381 - Proton Beam Therapy Centre material use, architectural technology and performance
-
FOI/2024/0385 - Immunoglobulin vials (by brands) distributed to patients
-
FOI/2024/0393 - Translation service/ communication spend
-
FOI/2024/0394 - Private maternity services 2012, 2016, 2018, 2022 and 2023
-
FOI/2024/0395 - Treatment and services for duchenne muscular dystrophy
-
FOI/2024/0400 - Gestational Diabetes Mellitus (GDM) screening and fetal outcomes
-
FOI/2024/0412 - Healthcare travel costs scheme for patients